Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A
By preferentially promoting cAMP-mediated intracellular pathways, thought to be central to insulin secretion and appetite regulation, this receptor bias may enhance metabolic efficacy while potentially reducing the activation of alternative signalling cascades associated with receptor desensitisation or adverse effects (although the clinical relevance of this remains to be fully established)
A small change in lean mass on a scan may be less concerning than a patient who reports: New falls or near-falls Progressive weakness Difficulty getting out of a chair Reduced walking tolerance Inability to perform usual daily activities Persistent dizziness or dehydration Severe appetite loss Inability to consume adequate nutrition Loss of training capacity Rapid, unplanned, or poorly tolerated weight loss These are not simply body-composition issues
Gerstein HC, Miller ME, Byington RP, Goff DC, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH, et al: Effects of intensive glucose lowering in type 2 diabetes
If semaglutide has not produced the results you want, switching to tirzepatide through Prime Health or another provider is a reasonable next step
